Sigilon Therapeutics Stock Net Income
Sigilon Therapeutics fundamentals help investors to digest information that contributes to Sigilon Therapeutics' financial success or failures. It also enables traders to predict the movement of Sigilon Stock. The fundamental analysis module provides a way to measure Sigilon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sigilon Therapeutics stock.
Sigilon |
Sigilon Therapeutics Company Net Income Analysis
Sigilon Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Sigilon Therapeutics Net Income | (43.56 M) |
Most of Sigilon Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sigilon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Sigilon Therapeutics reported net income of (43.56 Million). This is 112.76% lower than that of the Biotechnology sector and 162.19% lower than that of the Health Care industry. The net income for all United States stocks is 107.63% higher than that of the company.
Sigilon Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sigilon Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sigilon Therapeutics could also be used in its relative valuation, which is a method of valuing Sigilon Therapeutics by comparing valuation metrics of similar companies.Sigilon Therapeutics is currently under evaluation in net income category among its peers.
Sigilon Fundamentals
| Return On Equity | -0.76 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (1.71) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 28.99 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 8.69 % | |||
| Shares Owned By Institutions | 54.33 % | |||
| Number Of Shares Shorted | 8.23 K | |||
| Price To Book | 0.25 X | |||
| Price To Sales | 0.87 X | |||
| Revenue | 12.94 M | |||
| Gross Profit | (24.69 M) | |||
| EBITDA | (41.27 M) | |||
| Net Income | (43.56 M) | |||
| Cash And Equivalents | 88.21 M | |||
| Cash Per Share | 2.72 X | |||
| Total Debt | 28.06 M | |||
| Debt To Equity | 0.61 % | |||
| Current Ratio | 2.77 X | |||
| Book Value Per Share | 10.97 X | |||
| Cash Flow From Operations | (51.47 M) | |||
| Short Ratio | 0.11 X | |||
| Earnings Per Share | (14.83) X | |||
| Target Price | 47.33 | |||
| Number Of Employees | 62 | |||
| Beta | 4.12 | |||
| Market Capitalization | 56.22 M | |||
| Total Asset | 87.28 M | |||
| Retained Earnings | (256.8 M) | |||
| Working Capital | 43.42 M | |||
| Z Score | -3.73 | |||
| Net Asset | 87.28 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |